U.S., EU Back Pharma in Denying Access to Lifesaving COVID Products

A compromise effort to waive intellectual-property rights for vaccines, treatments, and tests will do little to expand supply, experts believe.


You can count on the Prospect, can we count on you?

There's no paywall here. Your donations power our newsroom as we report on ideas, politics and power — and what’s really at stake as we navigate another presidential election year. Please, become a member, or make a one-time donation, today. Thank you!